VITEK 2 GRAM NEGATIVE DORIPENEM

K082346 · bioMerieux, Inc. · LON · Mar 16, 2009 · Microbiology

Device Facts

• Record ID: K082346
• Device Name: VITEK 2 GRAM NEGATIVE DORIPENEM
• Applicant: bioMerieux, Inc.
• Product Code: LON · Microbiology
• Decision Date: Mar 16, 2009
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.1645
• Device Class: Class 2

Intended Use

VITEK® 2 Gram Negative Doripenem is designed for antimicrobial susceptibility testing of Gram negative microorganisms and is intended for use with the VITEK 2 and VITEK 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK 2 Gram Negative is a quantitative test. Doripenem has been shown to be active against the microorganisms listed below according to the FDA label for the antimicrobial. Active in vitro and in clinical infections: Acinetobacter baumannii Escherichia coli Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Active in vitro but clinical significance unknown: Citrobacter freundii Enterobacter cloacae Enterobacter aerogenes Klebsiella oxytoca Serratia marcescens The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 and VITEK® 2 Compact Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gramnegative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus agalactiae, and S. pneumoniae.

Device Story

VITEK®2 AST system determines antimicrobial susceptibility of bacterial isolates; uses VITEK®2 AST cards inoculated with standardized organism suspension. Instrument incubates cards; performs continuous optical monitoring via transmittance optics to measure organism growth. Algorithm uses predetermined growth thresholds and discriminate analysis to calculate Minimum Inhibitory Concentration (MIC) and category interpretation (SIR). Used in clinical laboratories by technicians; results reported to clinicians for antibiotic therapy decision-making. Benefits include automated, standardized susceptibility testing to guide appropriate antimicrobial treatment.

Clinical Evidence

Bench testing only. External evaluation compared VITEK 2 Gram Negative Doripenem performance against CLSI broth microdilution reference method using fresh and stock clinical isolates and stock challenge strains. Demonstrated 97.9% overall Category Agreement. Reproducibility and Quality Control results were acceptable.

Technological Characteristics

Miniaturized doubling dilution technique for MIC determination. Card contains antimicrobial medium rehydrated by saline-diluted bacterial isolate. VITEK 2 system provides automated incubation and optical growth monitoring. Connectivity: VITEK 2/VITEK 2 Compact instrument platforms. Software-based analysis of growth kinetics.

Indications for Use

Indicated for antimicrobial susceptibility testing of isolated colonies of aerobic Gram-negative bacilli (including Acinetobacter baumannii, E. coli, K. pneumoniae, P. mirabilis, P. aeruginosa, Citrobacter spp., Enterobacter spp., K. oxytoca, M. morganii, S. marcescens) using VITEK 2/VITEK 2 Compact systems.

Regulatory Classification

Identification

A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.

Special Controls

*Classification.* Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”

Predicate Devices

• VITEK® 2 Gram Negative Levofloxacin (k072038)

Submission Summary (Full Text)

{0}------------------------------------------------

82346 MAR 1 6 2009

## BIOMÉRIEUX

### 510(k) SUMMARY

## VITEK® 2 Gram Negative Doripenem

#### 510(k) Submission Information:

bioMérieux, Inc. Submitter's Name: 595 Anglum Road Address: Hazelwood, MO 63042 Contact Person: Jolyn Tenllado Associate Staff Regulatory Affairs Specialist 314 -731-8386 Phone Number. Fax Number: 314-731-8689 August 14, 2008 Date of Preparation: B. Device Name:

#### Formal/Trade Name: VITEK® 2 Gram Negative Doripenem (≤ 0.12 - ≥ 8 µg/ml) Classification Name: Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Device, 21 CFR 866.1645 VITEK 2 AST-GN Doripenern Common Name: C. Predicate Device: VITEK 2 Gram Negative Levofloxacin (K072038)

#### D. 510(k) Summary:

VITEK® 2 Gram Negative Doripenem is designed for antimicrobial susceptibility testing of Gram negative microorganisms. It is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. Doripenem has been shown to be active against the organisms listed below according to the FDA label for the antimicrobial.

Active in vitro and in clinical infections: Acinetobacter baumannii Escherichia coli Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa

Active in vitro but clinical significance unknown: Citrobacter freundii Enterobacter cloacae Enterobacter aerogenes Klebsiella oxytoca Morganella morganii Serratia marcescens

#### bioMérieux, Inc.

800/638-4835 Fax: [phone] Anglum Road, Hazelwood, Missouri 63042-2320, USA Phone: [phone]

{1}------------------------------------------------

The antimicrobial presented in VITEK 2 AST Cards is in concentrations equivalent by efficacy to standard method concentrations in mog/ml. The VITEK 2 AST Cards are essentially miniaturized versions of the doubling dilution technique for determining the minimum inhibitory concentration (MIC) microdilution methodology.

The bacterial isolate to be tested is diluted to a standardized concentration in 0.45 - 0 .50% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK 2 System automatically fills, seals and places the card into the incubator/reader. The VITEK 2 Compact has a manual filling and sealing operation. The VITEK 2 monitors the growth of each well in the card over a defined period of time (up to 18 hours). At the completion of the incubation cycle, a report is generated that contains the MIC value along with the interpretive category result for each antibiotic contained on the card.

VITEK 2 Gram Negative Doripenem demonstrated substantially equivalent performance when compared with the CLSI broth microdilution reference method, as defined in the FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA, Issued March 5, 2007.

The Premarket Notification (510(k)) presents data in support of VITEK 2 Gram Negative Dorioenem. An external evaluation was conducted with fresh and stock clinical isolates and stock challenge strains. The external evaluations were designed to confirm the acceptability of VITEK 2 Gram Negative Doripeners by companing its performance with the CLSI broth microditution reference method. The data is representative of performance on both the VITEK 2 Compact instrument platforms, as evidenced in the AST equivalency study presented in the VITEK 2 Compact 510(k), K050002. VITEK 2 Gram Negative Doripenem demonstrated acceptable performance of 97.9% overall Category Agreement. Reproducibility and Quality Control demonstrated acceptable results.

{2}------------------------------------------------

Image /page/2/Picture/0 description: The image shows the text "DEPARTMENT OF HEALTH & HUMAN SERVICES". The text is in all caps and is in a sans-serif font. The text is centered on the image and is the only element present.

Image /page/2/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features a stylized eagle with three lines representing its wings and body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular pattern around the eagle.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

# MAR 1 6 2009

Ms. Jolyn Tenllado Associate Staff Regulatory Affairs Specialist bioMérieux 595 Anglum Road Hazelwood, MO 63042

Re: k082346

> Trade/Device Name: VITEK® 2 Gram Negative Doripenem (≤ 0.12 -> 8 µg/ml) Regulation Number: 21 CFR 866.1645 Regulation Name: Short-Term Antimicrobial Susceptibility Test System Regulatory Class: Class II Product Code: LON Dated: March 12, 2009 Received: March 13, 2009

Dear Ms Tenllado:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

{3}------------------------------------------------

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)). please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely vours.

Sally attaym

Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

# Indications for Use

1082346 510(k) Number (if known):

Device Name: VITEK® 2 Gram Negative Doripenem (≤ 0.12 - ≥ 8 µg/ml)

Indications For Use:

VITEK® 2 Gram Negative Doripenem is designed for antimicrobial susceptibility testing of Gram negative microorganisms and is intended for use with the VITEK 2 and VITEK 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK 2 Gram Negative is a quantitative test. Doripenem has been shown to be active against the microorganisms listed below according to the FDA label for the antimicrobial.

Active in vitro and in clinical infections: Acinetobacter baumannii Escherichia coli Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa

Active in vitro but clinical significance unknown: Citrobacter freundii Enterobacter cloacae Enterobacter aerogenes Klebsiella oxytoca Serratia marcescens

The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 and VITEK® 2 Compact Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gramnegative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus agalactiae, and S. pneumoniae.

Prescription Use (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Saiyala
Division Sign-Off

Page 1 of 1

Office of In Vitro Diagnostic Device Evaluation and Safety

51000 . Ror 23 66

p. 9